Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Conditions
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent B-Cell Prolymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent High Grade B-Cell Lymphoma
- Recurrent Indolent Non-Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Refractory B-Cell Prolymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory High Grade B-Cell Lymphoma
- Refractory Indolent Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Transformed Chronic Lymphocytic Leukemia
- Refactory Childhood Acute Lymphoblastic Leukemia
- Refractory Childhood Non-Hodgkin Lymphoma
Interventions
- BIOLOGICAL: Anti-CD19/CD20/CD22 CAR T-Cells
- DRUG: Cyclophosphamide
- DRUG: Fludarabine Phosphate
- PROCEDURE: Echocardiography
- PROCEDURE: Multigated Acquisition Scan
- PROCEDURE: Biopsy
- PROCEDURE: Pheresis
- PROCEDURE: Bone Marrow Aspiration and Biopsy
- PROCEDURE: Biospecimen Collection
Sponsor
Sumithira Vasu
Collaborators